“Sweet Spot” of Schering’s R and D Pipe-line Includes Drug Being Bounced by FDA. . . .

At today’s web-cast, Mr. Hassan highlighted Schering’s top three not-yet-US-approved drug candidates — including Bridion, or sugammadex:

. . ..We believe we’re hitting the sweet spot on R&D and patent exclusivity. . . .

– Fred Hassan,
CEO Schering-Plough,
November 24, 2008

But wait, Fred — FDA rejected that application — in June 2008. I know you are working on it with FDA — just as three years ago, you predicted the launch, in 2009 to 2010 of several of the drug candidates you now “aspire” to have initially-filed with FDA. So, each of those is about three to four years behind where you earlier said each would be.

Gee, that’s an oddly-shapen “sweet spot“, Mr. Hassan.